瑞舒伐他汀钙对2型糖尿病患者动脉粥样硬化的影响

摘要

目的 探讨瑞舒伐他汀钙对2型糖尿病(T2DM)患者颈动脉内膜中层厚度(C-IMT)及斑块、血清高敏C-反应蛋白(hs-CRP)、脂联素水平的影响.方法 76例T2DM患者分为观察组和对照组,各38例.所有入选患者均口服降糖药物治疗.观察组在上述治疗基础上口服瑞舒伐他汀钙,观察24周.观察两组患者治疗前后C-IMT和斑块积分,血清hs-CRP和血清脂联素水平.结果 两组治疗后C-IMT及斑块积分均较治疗前显著降低(P＜0.05);观察组降低的更加明显(P＜0.05);2组治疗后hs-CRP水平较治疗前显著降低(P＜0.05),脂联素水平较治疗前显著增加(P＜0.05);与对照组治疗后比较,观察组降低/增加的更加明显(P＜0.05).结论 瑞舒伐他汀钙可明显减轻T2DM患者的动脉粥样硬化程度,其除调脂外还可能与降低hs-CRP水平、升高血清脂联素水平部分有关有关.%Objective To observe the effect of rosuvaslalin calcium on the levels of C-IMT and plaque, serum hs-CRP, adiponeclin in palienls of type 2 diabeles with atherosclerosis. Methods 76 palienls with T2DM were divided into observe groups and the conlrol group. All palienls were trealed wilh oral hypoglycemic medication. Observe group was given rosuvaslalin calcium on the basis of oral hypoglycemic medication. C-IMT and plaque score, serum of hs-CRP, serum adiponeclin levels in the two groups were compared before and after the treatment. Results After the treatment, the C-IMT and plaque score were significantly lower (P < 0. 05) compared wilh treatment;serum hs-CRP and adiponeclin levels were significantly lower than those before treatment (P <0. 05); C-IMT, plaque score, serum hs-CRP and adiponeclin in observe group were markedly lower than those in conlrol group(P <0. 05) . Conclusion Rosuvaslalin calcium can significantly improve atherosclerosis in palienls wilh T2DM, which may be associated to its effects in reducing hs-CRP levels, increased serum adiponeclin levels beyond its lipid-lowering role.